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1. INTRODUCTION 
1.1. STUDY BACKGROUND 
Subclinical hypothyroidism (SCH) is a common finding in older people across 
Europe, and is a likely contributor to multiple problems in older age. There is 
the potential for multisystem benefits from treatment of SCH with 
Levothyroxine. 
1.2. STUDY OBJECTIVES 
To test the efficacy of thyroxine replacement for subclinical hypothyroidism 
(SCH) in adults aged 65 years and older. 
1.3. STUDY DESIGN 
Randomised double-blind placebo-controlled parallel group trial. 
1.4. SAMPLE SIZE AND POWER 
1.4.1. INITIAL SAMPLE SIZE CALCULATION 
To detect a hazard ratio (HR) of 0.75 would need 379 events in total for 80% 
power at the 5% level (2-tailed). It is likely that drop-ins/drop outs will reduce 
the intention-to-treat effect. The drop-in and drop-out rates are each 
estimated to be less than 5% at 1 year and less than 10% at the end of the 
study. If the treatment effect is attenuated to a HR of 0.79 then 565 events in 
total would give 80% power. With an average follow-up of 3 years, 
observations from a similar age and risk population give an expected 
cardiovascular event rate of around 21%. 3000 subjects (1500 Levothyroxine, 
1500 placebo) would have to be recruited. 
1.4.2. REVISED SAMPLE SIZE CALCULATION 
Given the projections for recruitment during the study, it became clear that it 
would not be possible to accrue the required number of events to achieve the 
above power. Event-free survival has therefore been dropped as a primary 
outcome and change in disease specific QOL (ThyPRO) hypothyroid function 
and tiredness are now co-primary outcomes.  
Power calculations were revised for total recruitment numbers of 540 and 
750, and with mean follow-up of 18 months. The global significance level is 
split equally between the two co-primary outcomes. A 9 unit change is a 
realistic and clinically meaningful effect size. 
The addendum to the protocol v6.0 (page 60) states: 
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“Observed SDs for data at visit 5 (1-year) values adjusted for baseline are 
13.3 and 18.3 (on 100-point (%) scales) for hypothyroid and tiredness scales 
respectively. 
We will have 80% power to detect a change with levothyroxine treatment of 
3.5% (3.0%) on the hypothyroid scale with total sample sizes of 540 (750). 
We will have 80% power to detect a change of 4.9% (4.1%) on the tiredness 
scale with total sample sizes of 540 (750).” 
1.5. STUDY POPULATION 
Potential subjects will be identified from clinical laboratory databases as 
having biochemical features consistent with SCH, (thyroid stimulating 
hormone [TSH] of >4.6 and <19.9 mU/L plus free thyroxine levels within the 
laboratory reference range). 
1.5.1. INCLUSION CRITERIA 
Community-dwelling subjects aged ≥65 years with SCH, diagnosed on the 
basis of elevated TSH levels (≥4.6 and ≤19.9 mU/L) and free thyroxine levels 
(fT4) within the laboratory reference range, measured on a minimum of two 
occasions at least 3 months apart (in Switzerland there was a minor variation 
the main study protocol - patients required only one measure of fT4 before 
recruitment). 
1.5.2. EXCLUSION CRITERIA 
 Subjects currently on (anti)thyroid drugs, amiodarone or lithium; 
 Recent thyroid surgery or radio-iodine; 
 Grade IV NYHA heart failure; 
 Prior clinical diagnosis of dementia; 
 Recent hospitalisation for major illness; 
 Recent acute coronary syndrome; 
 Acute myocarditis or acute pancarditis; 
 Untreated adrenal insufficiency or adrenal disorder; 
 Terminal illness; 
 Participants with rare hereditary problems of galactose intolerance, the 
Lapp lactase deficiency or glucose-galactose malabsorption; 
 Subjects who are participating in ongoing RCTs of therapeutic 
interventions (including CTIMPs); 
 Plan to move out of the region in which the trial is being conducted 
within the next 2 years. 
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1.6. STATISTICAL ANALYSIS PLAN (SAP) 
1.6.1. SAP OBJECTIVES 
The objective of this SAP is to describe the statistical analyses to be carried 
out for the Final Analysis of the TRUST study. 
1.6.2. GENERAL PRINCIPLES 
Data will be summarised overall and by treatment group. Continuous 
variables will be summarised as number of observed values, number of 
missing values, mean and standard deviation, median and interquartile range 
and minimum and maximum. Categorical data will be summarised as number 
of observed values, number of missing values, number and percentage in 
each category. 
Recruitment data will be presented by “study centre”, defined as participants 
recruited in (i) Scotland, (ii) Netherlands, (iii) Ireland, (iv) Switzerland. 
Continuous efficacy outcomes involving measurement at follow-up and 
baseline will be analysed as change from baseline at each time point 
comparing treatment groups and adjusting for stratification variables and 
baseline levels of the same variable using linear regression. In addition, data 
items measured at more than one follow-up time will be analysed using 
repeated measures regression analyses and in terms of the final assessment 
for each participant. 
Continuous efficacy outcomes measured at final follow-up only will be 
compared between treatment groups using linear regression adjusting for 
stratification variables. 
For all efficacy outcomes measured at baseline and final visit, additional 
exploratory analyses that adjust for time from baseline to final visit will be 
carried out. 
Distributions of the residuals will be reviewed and will be taken into 
consideration in assessing whether or not additional analyses based on 
transformations should be carried out.  
When calculating ThyPRO scores, valid raw total scores containing missing 
items will be scaled so that the maximum possible score is maintained. 
Analyses of haemoglobin levels will be further adjusted for the laboratory at 
which they were measured. 
Time-to-event outcomes will be compared between groups using Cox 
proportional hazards regression models adjusting for stratification variables. 
Time to event curves will be based on the Kaplan-Meier method. 
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Stratification variables are 
 Site  
 Gender 
 Starting dose of levothyroxine 
All efficacy analyses will be carried out on the intention to treat population. 
Safety analyses will be carried out on the ITT population. The main analyses 
will be modified ITT based on participants with data on the outcome of 
interest. These analyses will be supported with sensitivity analyses using 
mixed effects models and multiple imputation. Primary analyses and 
secondary will be repeated on the per protocol population as exploratory 
analyses. 
The two-sided significance level for each primary outcome is 0.025.  
1.6.3. CURRENT PROTOCOL 
At the time of writing, the current protocol for the TRUST study is version 6.0, 
dated 19/01/2016. 
Future amendments to this protocol will be reviewed for their impact on this 
SAP, which will be updated only if necessary. If no changes are required to 
this SAP following future amendments to the study protocol, this will be 
documented as part of the Robertson Centre Change Impact Assessment 
processes. 
1.6.4. SOFTWARE 
Analyses will be carried out using R for Windows v3.0.1, SAS for Windows 
v9.3, or higher versions of the programs. 
2. ANALYSIS 
2.1. STUDY POPULATIONS 
The intention-to-treat (ITT) population consists of all participants randomised 
excluding those randomised in error. 
Modified ITT populations will include ITT participants who have data for the 
outcome of interest. For analyses at the 12 month visit to be valid, they must 
have been conducted at 12 months ± 31 days after randomisation. 
Per-protocol (PP) populations consists of all participants in the ITT population 
who  
 have data for the outcome variable of interest; 
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 are on treatment at the time of the analysis being conducted, i.e. they 
have not withdrawn from treatment and, if they are in the active 
treatment group, they have not been down-titrated to 0; 
 have had their 12 month visit at 12 months ± 31 days after 
randomisation; 
 do not have any other major protocol violation identified prior to 
database lock.  
Reasons for exclusion from PP populations will be summarised. 
 
2.2. STUDY STATUS AND CONSORT DIAGRAM 
A study status table will be created describing the numbers consented and 
validly randomised, the numbers consented and not validly randomised with 
reasons. 
The table will contain the numbers who are dead, withdrawn from 
randomised treatment, who have withdrawn consent and are lost to follow-up 
at the 12 month visit at which the primary outcomes will be assessed, and at 
the end of the study. 
The table will contain the numbers included in the main analysis of the 
primary outcome for both the ITT and PP populations. 
This table will be used to create a CONSORT diagram for the trial. 
2.3.  VISIT ATTENDANCE 
For each visit, the number and percentage who attended the visit, missed the 
visit, had completed the study before the visit, had withdrawn from follow-up 
or had died before the visit will be reported. A visit will be considered as 
attended if any measurement or participant reported data for this visit are 
available. A visit will be considered as missed if there are no data for this visit 
and the participant has not died, not completed the study and not withdrawn 
from follow-up.  
2.4. BASELINE CHARACTERISTICS 
The following baseline characteristics will be summarised overall and by 
treatment group (an additional tabulation will be created for ITT participants 
by inclusion/exclusion from the modified ITT analysis for the primary 
outcome): 
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 age (continuous and categorical as <80 and ≥80), gender, ethnicity, 
smoking history, alcohol consumption, living arrangements, height; 
 cardiovascular risk factors (MI, angina, stroke, TIA, heart failure, PVD, 
revascularisation, AF, hypertension, diabetes); 
 medical history (epilepsy, dementia, osteoporosis, hereditary galactose 
intolerance, other major illness); 
 laboratory measures; TSH, fT4, and haemoglobin at baseline; 
 single lead ECG results (heart rate, cardiac rhythm); 
 baseline values of outcome measures (see Section 2.5.2.); 
 use of concomitant medications, using the WHO ATC classification 
system level 1 and 2, ordered by ATC code. 
2.5. EFFICACY OUTCOMES AT 12 MONTHS 
2.5.1. PRIMARY OUTCOME 
Disease-specific quality of life and symptom burden will be analysed as 
follows in the modified ITT (primary) and PP populations: 
 Change from baseline in ThyPRO hypothyroid symptoms score. 
This outcome will be analysed in the modified ITT population as 
The estimated treatment effect (p-value and 95%CI) in a linear 
regression model predicting change from baseline to 12 month 
visit in ThyPRO hypothyroid symptoms score with the following 
covariates: randomised treatment, ThyPRO hypothyroid 
symptoms score at baseline and stratification variables. 
 
 Change from baseline in ThyPRO fatigue score. This outcome will be 
analysed analogously. 
 Statistical significance for each primary outcome requires P ≤ 0.025. 
 
2.5.2. SECONDARY OUTCOMES 
The following secondary outcomes will be analysed at 12 months in the 
modified ITT (primary) and PP populations 
 General QoL (EQ-5D) 
 Handgrip strength 
 Haemoglobin 
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 Blood pressure 
 Weight, waist circumference and BMI. 
 
These variables will be analysed as for the primary outcomes. 
 
2.5.3. SENSITIVITY ANALYSES 
Sensitivity analysis for the modified ITT analyses for the primary and 
secondary outcomes at 12 months will be carried out using a) multiple 
imputation of missing values using a model containing age, sex, baseline TSH 
and any available outcome measurements recorded prior to 12 months and b) 
using mixed model repeated measures analysis. 
2.5.4. SUBGROUP ANALYSES 
The primary and secondary outcomes at 12 months will also be analysed in 
the following subgroups by adding the subgroup variable and its interaction 
with treatment group: 
 Gender (Male/Female) 
 Baseline TSH  
o <10 / ≥10 
o <7 / 7-9.99 / ≥10 
In addition, continuous interactions with age at randomisation and baseline 
TSH will be analysed analogously. 
2.6. EFFICACY OUTCOMES AT END OF STUDY 
The following measurements will be assessed at baseline and the end of 
study visit: 
 
 ThyPRO hypothyroid symptoms and fatigue scores 
 General QoL (EQ-5D) 
 Handgrip strength 
 Cognitive function (letter digit coding test (LDCT),  
 Functional ability (Barthel index, IADL) 
 Haemoglobin 
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 Blood pressure 
 Weight, waist circumference and BMI 
 
These outcomes will be analyses as for the primary outcome. An additional 
sensitivity analysis will be carried out adjusting for the time from baseline to 
the measurement assessment. 
 
The following outcomes will be assessed at the end of study as described 
below: 
 Comprehensive thyroid quality of life assessment ThyPRO39 at the end 
of study visit 
The estimated treatment effect (p-value and 95%CI) in a linear 
regression model predicting end of study ThyPRO39 score with 
the following covariates: randomised treatment and stratification 
variables. 
 
 Fatal and non-fatal cardiovascular events (confirmed by Endpoint 
Adjudication Committee) 
The estimated treatment effect (p-value and 95%CI) in a Cox 
proportional hazards models containing randomised treatment 
group and stratification variables. 
 Fatal cardiovascular events (confirmed by Endpoint Adjudication 
Committee). This outcome will be analysed analogously. 
 All-cause mortality. This outcome will be analysed analogously. 
 
2.7.  EFFICACY OUTCOMES AT OTHER TIMEPOINTS 
All outcomes assessed post randomisation at timepoints other than baseline, 
12 months and end of study will be investigated as change from baseline at 
these timepoints, analysed as for the primary outcome. 
In addition, change from baseline for outcomes analysed at two or more post 
randomisation visits will be analysed using repeated measures ANOVA models 
with general covariance structures, first containing only treatment group, 
study visit, the baseline value of the outcome being assessed and 
stratification variables and then including a treatment by study visit 
interaction.  
  
TRUST Statistical Analysis Plan v1.0 (20/05/2016) Page 11 of 12 
 
 
 
Results at each time point and changes from baseline will also be presented 
graphically as means and 95% CIs at each time point. 
 
 
2.8. SAFETY OUTCOMES 
2.8.1. STUDY TREATMENT 
Starting dose and dose just before 2, 12, 24, 36 month visits, current dose at 
final visit and dose at the end of the titration phase in year 1 will be 
summarised overall and by treatment group.  
Time to permanent withdrawal from study treatment (excluding deaths) will 
presented using Kaplan-Meier time-to-event curves and compared using log-
rank statistics. Reasons for permanent withdrawal from study treatment will 
be tabulated overall and split by treatment group. 
2.8.2. WITHDRAWALS FROM THE STUDY 
Numbers withdrawn from the study and the main reasons for withdrawal will 
be summarised overall and by treatment group. Kaplan-Meier plots for time to 
withdrawal will be produced. 
2.8.3. SERIOUS ADVERSE EVENTS 
The number and characteristics of SAEs will be summarised. The number and 
percentage of participants experiencing at least one SAE will be summarised 
overall and by MedDRA System Organ Class and preferred term. These 
summaries will be repeated for SAEs at least possibly related to study 
medication, and for fatal events. Tabulations will be sorted by the MedDRA 
SOC term order and by preferred term order with in SOCs. 
The incidence of other safety outcomes of particular interest (hypothyroidism, 
atrial fibrillation, heart failure, fractures), will be summarised separately. 
Kaplan-Meier plots by treatment for the time to the first occurrence of each 
safety outcome of particular interest will be produced. Time to event will be 
compared between groups using log-rank tests. If there are sufficient events, 
Cox proportional hazards regression adjusting for stratification variables will 
be used. 
2.8.4. CONCOMITANT MEDICATIONS 
The number and percentage of participants receiving at least one concomitant 
medication will be summarised by ATC codes level 1 and 2. 
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2.8.5. OTHER SAFETY DATA 
 ThyPRO hyperthyroid symptoms will be summarised at each time point, 
overall and by treatment group. Change in ThyPRO hyperthyroid 
symptoms will be compared between treatment groups in the same 
way as the primary analysis. 
 A listing of deaths will be provided. 
3. DOCUMENT HISTORY 
This is version 1.0 (initial creation) of the SAP for the final analysis for TRUST, 
dated 20/05/2016. 
4. TABLES AND FIGURES 
The layout of the tables and figures will be finalised based on tables created 
using dummy treatment codes prior to database lock. 
5. LISTINGS 
 All SAEs will be listed.  
 
